Purification and Labeling of human MLH1-PMS1 by Lew, Rachel
  
 
 
 
 
Purification and Labeling of human MLH1-PMS1 
Undergraduate Research Thesis 
 
Presented in Partial Fulfillment of the Requirements for Graduation “with Honors Research 
Distinction in Microbiology” in the undergraduate colleges of The Ohio State University 
 
By  
Rachel Lew 
 
The Ohio State University  
May 2020  
 
Project Advisor: Dr. Richard Fishel, Department of Cancer Biology and Genetics  
  
Abstract 
A common mechanism that many species have to repair errors in DNA replication is 
DNA mismatch repair. Mutations in the proteins involved in this mechanism correspond with an 
accumulation of mismatched nucleotides. The accumulation of mismatched nucleotides can lead 
to cancers or DNA instability (3,5). For example, Huntington’s Disease, a trinucleotide repeat 
disease, results after DNA mismatch repair proteins cause trinucleotide repeat-induced DNA 
instability (5). Furthermore, Lynch syndrome corresponds to a defective mismatch repair system 
and people who inherit this disease have a higher risk of developing colorectal cancer (3).  
The two critical proteins in the mismatch repair system are MutS and MutL. MutS 
searches the DNA for a mismatch, and once a mismatch is recognized, it loads MutL. Once both 
of these proteins are on the DNA, the mismatch repair can proceed (3).  Of the human MutL 
homologs, MLH1-PMS1 has not been studied comprehensively because it is a much weaker 
genetic mutator than the other homologs and it does not have the latent endonuclease activity 
that MLH1-PMS2 has (1). However, evidence suggests that MLH1-PMS1 functions in MSH2-
MSH3 mismatch repair. 
A protocol to purify and label this protein using chromatography and sortase labeling is 
presented so that the purified protein can be used in single molecule experiments. Further 
investigation of this protein will likely provide insight on the mismatch repair mechanism, Lynch 
syndrome, and trinucleotide repeat diseases such as Huntington’s disease.   
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Introduction  
Mismatch repair (MMR) is a highly conserved process that identifies and fixes nucleotide 
mismatch errors that propagate during the process of DNA replication. These nucleotide 
mismatches are attributed to a variety of causes, including polymerase misincorporation errors, 
recombination between heteroallelic parental DNAs, and chemical/physical damage to 
nucleotides. Failure of MMR corresponds with an abundance of mispaired nucleotides, 
culminating in an accumulation of genetic mutations that can cause DNA instability or cancer 
(3,5,7). Thus, the importance of mismatch repair on the development of diseases cannot be 
understated.  
Huntington’s Disease, which causes the breakdown of nerve cells in the brain, 
corresponds to DNA instability due to the accumulation of trinucleotide repeats (5). In particular, 
it has been demonstrated that MSH2 is accountable for almost 100% of (CAG)·(CTG) repeat 
expansions in this disease and mutations in MSH2 eliminate the presence of these expansions 
(11). Furthermore, studies have shown that mutations in MSH3, rather than MSH6, eliminates 
the presence of trinucleotide repeat expansions as well (13). It is estimated that the possibility of 
passing Huntington’s Disease onto progeny is 50% and that overall, 5.70 out of 10,000 people 
are affected (5,10). On the other hand, 
Lynch syndrome, the most common 
hereditary colorectal cancer condition 
which is estimated to affect about 1 in 370 
Figure 1. Basic Mismatch Repair Scheme 
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to 1 in 2000 people (9), is caused by autosomal dominant mutations in the mismatch repair genes 
and results in the accumulation of nucleotide alterations (3,7,12). As such, there is considerable 
value, when investigating Huntington’s Disease, Lynch Syndrome, and a host of other diseases, 
in attempting to understand the nature of mismatch repair and how faulty functioning among its 
many protein components has substantial consequences for human health. 
In Escherichia coli, MutS is an ADP-bound homodimer that acts as a short-lived sliding 
clamp to intermittently search DNA. Once a mismatch is recognized, MutS binds to the 
mismatch and releases ADP. It then binds ATP and forms a stable-long lived sliding clamp that 
randomly slides along the DNA until the ATP is hydrolyzed by the weak ATPase activity of 
MutS. This releases the clamp from the DNA and returns it to the ADP-bound state so that it can 
continue its search of the DNA (3,7). MutL, also a homodimer, is recruited to the DNA by ATP-
bound sliding MutS clamps where it binds ATP to form a second independent sliding clamp that 
can disassociate and re-associate with MutS. As a sliding clamp, MutL can then recruit MutH to 
nick the strand of DNA at hemi-methylated d(GATC) sites. This nick allows the proteins 
associated with the excision reaction to target the newly synthesized daughter strand and repair 
the mismatch. The MutL sliding clamp is released from the DNA upon ATP hydrolysis by the 
weak ATPase function of MutL(3,7). Other studies have shown that while this mechanism is 
similar in eukaryotes, such as yeast and humans, there are some differences and it is less 
understood (4). However, the conservation of processes such as recognition, removal, and re-
synthesis, is well-documented (3,6). 
  
E. coli Protein Summary 
MutS ADP-bound homodimer that searches the DNA 
for a mismatch. Once a mismatch is recognized, 
MutS binds to the mismatch and releases ADP. It 
then binds ATP and can recruit MutL to the DNA 
(3, 7). 
MutL Once recruited to the DNA, MutL binds ATP 
forms an independent sliding clamp that interacts 
with MutS. MutL can recruit MutH (3, 7).  
MutH Nicks the DNA at hemi-methylated d(GATC) 
sites (3,7).  
Table 1. Summary of mismatch repair protein functions in E. coli 
In humans, there are two MutS homologs that are capable of recognizing mismatches: 
MSH2-MSH6 and MSH2-MSH3. MSH2-MSH6 recognizes base-base mismatches or small 
insertion/deletion loops of 1-2 nucleotides, while MSH2-MSH3 recognizes larger insertion 
deletion loops of 1-14 nucleotides (2). Once the mismatch is recognized, the MutS homolog 
recruits and forms a complex with the MutL homolog, MLH1-PMS2 (3). In contrast to the 
prokaryotic E. coli mismatch repair system, the eukaryotic system does not have a homologous 
protein to MutH (6). However, the endonuclease activity of MLH1-PMS2, known to be activated 
by PCNA, is thought to do the nicking (3). Furthermore, after the DNA incision, the nicked DNA 
strand is removed. It is hypothesized that EXO1 is recruited to promote excision of the 
mismatched DNA. However, other mechanisms are possible. The mismatch repair pathway is 
completed by DNA polymerase and DNA ligase (6). 
Current literature has not elucidated a specific role for MLH1-PMS1 in MMR. In the 
past, PMS1 has not been studied as comprehensively as PMS2 because PMS1 lacks the 
endonuclease activity that PMS2 has. Furthermore, mice lacking PMS1 are not cancer prone, 
suggesting an alternate role for PMS1 in the mismatch repair system (1). Through co-
immunoprecipitation, it has been shown that MLH1 and PMS1 have a very high affinity for each 
other but molecules that interact with PMS1 are mainly proteins belonging to the ubiquitylation 
pathway, leading to a hypothesis that PMS1 could be post-translationally modified by ubiquitin. 
This polyubiquitylation may target PMS1 for proteasome-mediated degradation which might 
make MLH1 more available for PMS2 for mismatch repair (1). However, because many proteins 
get ubiquitylated in cells, the fact that PMS1 is ubiquitylated for the sole purpose of freeing up 
MLH1 is unlikely. Another hypothesis that seems to be more valid is that PMS1 participates in 
MSH2-MSH3 mismatch repair, which functions in repair of larger insertion-deletion loops. This 
claim is based on one of the MutL homologs in yeast, MLH1-MLH3, that is hypothesized to 
participate in MSH2-MSH3 mismatch repair because mutations in this protein cause an increase 
in the number of frameshift mutations (6). Thus, the importance of human MLH1-PMS1 seems 
to lie in reparation of mismatches in trinucleotide repeat diseases such as Huntington’s Disease 
or Myonic Dystrophy.  
Table 2. Summary of mismatch repair proteins in humans.   
Human Protein Summary 
MSH2-MSH6 Recognizes base-base mismatches and small 
insertion/deletion loops of 1-2 nucleotides (2) 
MSH2-MSH3 Recognizes large insertion/deletion loops of 1-14 
nucleotides (2) 
MLH1-PMS2 Has a latent endonuclease activity, that is 
activated by PCNA, which is thought to do the 
nicking (3) 
MLH1-PMS1 Function currently unknown but is hypothesized 
to participate in MSH2-MSH3 mismatch repair 
(1) 
 
Overview 
In this paper, a method of labelling and purifying MLH1-PMS1 will be presented so that 
this procedure can be used for future single-molecule experiments. The protein was labeled with 
a Sulfo-Cy5 dye using a sortase-mediated reaction and was purified using an FPLC with a Ni-
NTA, Q-Sepharose, and PBE column.   
Materials and Methods  
Subcloning and Expression 
A his6-tag and the sortase recognition site, CLPETGG, were added to the N-terminal end 
of PMS1 though PCR. The gene was then cloned into pFastBac through restriction digestion 
with BamHI and KpnI followed by ligation. The plasmid containing PMS1 was then transformed 
into E. coli XL10 Gold cells. Sequencing results confirmed the presence of the gene in the 
plasmid. In preparation of expression in Sf9 insect cells using guidelines from the Bac-to-Bac 
Baculovirus Expression System manual (Life Technologies), the gene was then transformed into 
DH10Bac E. coli. Blue/white selection was used to identify colonies that contained the 
recombinant bacmid.  The Sf9 insect cells were transfected with the purified recombinant bacmid 
to produce a baculoviral stock, which was titered up three times. Two viral stocks were used to 
express the recombinant protein in Sf9 insect cells: his-srt-PMS1 and wildtype MLH1. For a 
typical expression, four 200 mL cultures were expressed at 27°C with 1 mL of each viral stock. 
The cell pellets were collected 48 hours later and stored at -80°C in storage buffer (25 mM 
HEPES pH 7.8, 100 mM NaCl, 10% Glycerol, 10 mM Imidazole pH 8.0) for later use.  
Purification and Labelling 
The following buffers were used in the full purification of MLH1-PMS1.  
Ni Buffer A: 25 mM HEPES pH 7.8, 100 mM NaCl, 10% Glycerol, 10 mM Imidazole pH 8.0 
Ni Superloop Buffer : 25 mM HEPES pH 7.8, 800 mM NaCl, 10% Glycerol, 10 mM Imidazole 
pH 8.0 
Ni Buffer B : 25 mM HEPES pH 7.8, 100 mM NaCl, 10% Glycerol, 100 mM Imidazole pH 8.0 
Q-Sepharose Buffer A: 25 mM HEPES pH 7.8, 10% Glycerol 
Q-Sepharose Buffer B: 25 mM HEPES pH 7.8, 1 M NaCl, 10% Glycerol 
Dialysis Storage Buffer: 25 mM HEPES pH 7.8, 150 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 
20% Glycerol 
Four cell pellets were thawed on ice at 4°C and centrifuged at 41000 rpm for 1 hour at 
4°C. The supernatant was then injected onto a pre-equilibrated 3 mL Ni-NTA column at 0.15 
mL/min using an FPLC and washed with 40 mL of Ni Superloop Buffer. The protein was then 
washed with an additional 10 mL of Ni Buffer A to remove the high salt and stepped to Ni Buffer 
B for 10 mL to elute 10 mL of the protein in 0.2 mL fractions. A 10% SDS-PAGE gel was run 
and it was determined that the protein was only semi-pure.  
The semi-pure protein was labelled in a reaction containing 5x sortase, 115x Sulfo-Cy5 
dye, 13 nmol of protein, and 10 mM CaCl2. The labeling reaction was incubated at 4°C for 30 
minutes. 20 mM EDTA was used to stop the reaction. The labelled protein was then injected 
onto a pre-equilibrated 2 mL Q-Sepharose column at 0.15 mL/min and washed for 50 mL with 
10% Q-Sepharose Buffer B to prevent non-specific binding. A gradient to 60% Q-Sepharose 
Buffer B over 10 mL was used to elute the protein in 0.2 mL fractions. A 10% SDS-PAGE gel 
was run to determine the purity. However, while the protein bands for MLH1 and PMS1 
appeared on the gel, the protein was still only semi-pure.  
Next, the protein was injected onto a pre-equilibrated 2 mL PBE column at 0.15 mL/min 
to remove any further impurities and to obtain the best concentration. The protein was washed 
for 40 mL at 10% Q-Sepharose Buffer B to prevent non-specific binding and was eluted at 60% 
Q-Sepharose Buffer B for 10 mL in 0.2 mL fractions. Another 10% SDS-PAGE gel was run, and 
it was determined that the protein was pure with the exception of a 30 kDa band of unknown 
identity. The protein was dialyzed with Dialysis Storage Buffer and frozen for use in future 
single-molecule experiments.   
Results  
 An image of the 10% SDS-PAGE gel is not available for the Ni-NTA purification or the 
Q-Sepharose purification. However, after both purifications, it was clear that the purity was still 
questionable. After purification using the PBE column, the major protein peak was over fractions 
5, 6, and 7 (see Figure 2). The proteins were visualized on a 10% SDS-PAGE gel and there still 
seems to be some impurities (see Figure 3), but PMS1 (105.8 kDa) and MLH1 (84.6 kDa) are 
clearly present. Based on Figure 3, fraction 5 was chosen for future single molecule experiments 
because it seemed to have the highest amount of protein and the least amount of the unknown 30 
kDa band. The specificity of labeling is shown in Figure 4. There seems to be some non-specific 
labeling. However, the majority of the protein labeled is PMS1. Thus, all three column 
purifications resulted in 4.8 uM of pure protein that was 67% labeled (see Table 3). Further 
analyses will need to be done on the band of about 30 kDa, whose identity is currently unknown, 
to determine what protein it is.   
  
 Figure 2. Chromatograph of PBE column purification. The major protein peak is over fractions 
5, 6, and 7.  
 
Figure 3. Coomassie stain of MLH1-PMS1 after PBE column. From left to right: Fraction 5, 
Fraction 5, Fraction 6, Fraction 7, Ladder. An unknown 30 kDa band is also present (orange).  
                                                                  
 
 
Table 3. Total Pure Protein and Percent Labeled Protein 
Discussion  
Three columns (Ni-NTA, Q-Sepharose, and PBE) were used in order to purify MLH1-
PMS1, a protein hypothesized to be involved in MSH2-MSH3 mismatch repair, for single 
molecule experiments. Criteria for column selection was primarily based on previous protocols 
in the lab for purifications with the other MutL homolog, MLH1-PMS2. The Ni-NTA column 
was used for the initial purification of the protein as the his-tag binds to the nickel with high 
affinity. The protein was loaded in low salt and 10 mM imidazole to prevent non-specific 
 
Protein A280 Concentration 
of Cy5 Dye 
Total Pure 
Protein  
Percent Labeled 
MLH1-PMS1 0.683 3.22 uM 4.8 uM 67% 
Figure 4. Cy5 Scan of 10% SDS-PAGE gel in 
Figure 3. Shown here is Lane 1, Fraction 5.  
PMS1 
binding to the column. The intention of the subsequent high-salt wash was to further disrupt non-
specific binding and remove some impurities to obtain a purer protein product in the end. Elution 
of the protein off the column required an increase in the concentration of imidazole, which 
competes for binding to the nickel, to improve efficiency and more importantly obtain the 
highest concentration of protein in the smallest number of fractions possible.  
The labelling was carried out using a sortase-mediated reaction with a Sulfo-Cy5 dye, a 
method that has been used in the lab with favorable results because it specific, produces high 
labeling yields, and can be carried out under physiological conditions (8). The Sulfo-Cy5 peptide 
was prepared using a HPLC. In this reaction, sortase recognizes the CLPETGG motif at the N-
terminus end of PMS1 and cleaves the peptide bond between the threonine and the glycine 
residues using a catalytic cysteine. This generates a thioacyl intermediate. Subsequent 
nucleophilic attack by the N-terminus of PMS1 for the C terminus of the Sulfo-Cy5 peptide 
resolves the intermediate, which results in the formation of a covalent bond between the peptide 
probe and the protein (8). The conditions used for the reaction were determined in an effort to 
achieve the highest labelling possible and to push the equilibrium of the reaction towards product 
formation. A labelling efficiency of 67% was obtained, with back reactions from the final 
product and the reversible nature of the sortase reaction contributing to the decreased labelling 
efficiency (8). 
For better separation of the protein from other impurities, a Q-Sepharose anion exchange 
column was used. The protein was once again loaded in low salt to prevent non-specific binding 
and eluted at high salt. No other reagents were added to the buffers except for 25 mM Hepes pH 
7.8 to maintain physiological conditions and 10% glycerol, essential for maintaining protein 
stability. A gradient was employed to elute the protein so that the protein of interest would come 
off the column at a different concentration from the non-essential proteins. Following this step, 
the protein was loaded onto a PBE column to enhance its concentration. The same Q-Sepharose 
buffer stocks were used to purify this protein because the PBE column works in a similar 
fashion, meaning that the protein elutes off the column at high salt concentrations because it is an 
anion exchange column. In this case, the protein was stepped off the column so the highest 
concentration of protein could be obtained. After completion of this purification, the protein was 
~90% pure but the presence of impurities was still noted, highlighting a need to revisit the 
protocol in future experiments to improve yield and purity. 
The protein was relatively pure with the exception of a 30 kDa band appearing at the 
bottom of the gel. One hypothesis is that the band is PCNA (30 kDa), which ensures the 
processivity of DNA polymerase, because of PMS1’s similarity to PMS2 (3). Furthermore, a 
study involving co-immunoprecipitation experiments has shown that besides MLH1, PMS1 also 
interacts with RFC, a protein known to load PCNA onto the DNA during re-synthesis (1).  The 
true identity of the band, however, is currently unknown and further analyses involving mass 
spectrometry, as well as confirmation with existing standard protein weights, will need to be 
done to determine which protein it is.  
         While an important step to improving the purification protocol is determining the identity 
of the 30 kDa band, there are other ways in which better separation and concentration of the 
protein can be achieved. For example, using a shallower gradient with the PBE column could 
yield a higher concentration of the PMS1 while washes with slightly higher salt concentrations 
could decrease the amount of non-specific binding obtained. However, caution must be taken 
when increasing the salt concentration so as not to prematurely elute the protein. Furthermore, 
higher labelling efficiencies would yield better results in single-molecule experiments. Studies 
have shown that sortase labeling can achieve labeling efficiencies as high as 90% (8). So, 
increasing the amount of protein used or putting the label on the C-terminus could serve as viable 
methods to improve the amount of labelled protein.   
  
Conclusion  
MLH1-PMS1 was labelled with a Sulfo-Cy5 dye on the N-terminus and was purified 
using a Ni-NTA, Q-Sepharose, and PBE column. From this purification protocol, 4.8 uM of 
protein was obtained that was 67% labelled. An unknown 30 kDa band, hypothesized to be 
PCNA, was also purified alongside MLH1-PMS1. However, the true identity of the band will 
need to be determined in the future. The purified protein will be used for single-molecule 
experiments to study the interaction between MSH2-MSH3 and MLH1-PMS1 as well as any 
other proteins that this protein interacts with such as PCNA. These experiments can be used to 
elucidate the mechanism for trinucleotide repeat diseases such as Huntington’s Disease or even 
Lynch syndrome. With more insight into how this disease progresses, the odds of developing and 
discovering novel prevention methods and treatments are higher.  
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